Zusammenfassung
Nach psychopathologischen und neuroradiologisch-neuropathologischen Gesichtspunkten und im Hinblick auf Unterschiede in Therapie und Verlauf wurde von Crow (1980; 1985) und — mit etwas anderer Akzentuierung — von Andreasen u. Olsen (1982) eine Unterteilung schizophrener Syndrome in einen positiven und negativen Subtyp vorgeschlagen. Positivsymptome wie Wahn oder Halluzinationen wurden mit einer funktioneilen Überaktivität mesolimbischer dopaminerger Neuronensysteme, Negativsymptome wie Affektverflachung, gedankliche und sprachliche Verarmung, Antriebsstörungen und soziale Rückzugstendenzen hingegen mit strukturmorphologischen Hirnveränderungen in Zusammenhang gebracht. Während Positivsymptome in der Regel recht gut auf Neuroleptika — die alle mehr oder weniger stark Dopaminrezeptoren blockieren — ansprechen, ist deren Wirkung bei Negativsymptomatik häufig wenig zufriedenstellend (Johnstone et al. 1976; Weinberger et al. 1980), wenngleich diese Einschätzung nicht unwidersprochen geblieben ist (Goldberg 1985; Meltzer et al. 1986).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Andreasen NC, Olsen SA (1982) Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry 39: 789–794.
Arnt J, Hyttel J (1984) Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. J Neural Transm 60: 205–223.
Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–452.
Clark D, Hjorth S, Carlsson A (1985) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62: 1–52.
Corsini GU, Del Zompo M, Manconi S, Cianchetti C, Mangoni A, Gessa GL (1977) Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv Biochem Psychopharmacol 16: 645–648.
Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66–68.
Crow TJ (1985) The two-syndrome concept: origins and current status. Schizophr Bull 11: 471–486.
Cutler NR, Jeste DV, Karoum F, Wyatt RJ (1982) Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients. Life Sci 30: 753–756.
Davidson M, Kendler KS, Davis BM, Horvath TB, Mohs RC, Davis KL (1985) Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients. Psychiatry Res 16: 95–99.
Ferrier IN, Johnstone EC, Crow TJ (1984) Clinical effects of apomorphine in schizophrenia. Br J Psychiatry 144: 341–348.
Gerbaldo H, Demisch L, Lehmann C-O, Bochnik J (1988) The effect of OPC-4392, a partial dopamine receptor agonist, on negative symptoms: results of an open study. Pharmacopsychiatry 21: 387–388.
Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456.
Hollister LE, Davis KL, Berger PA (1980) Apomorphine in schizophrenia. Comm Psyehopharmacol 4: 277–281.
Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L (1976) Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet II: 924–926.
Kammen DP van, Kammen WB van, Mann LS, Seppala T, Linnoila M (1986) Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 43: 978–983.
Levy MI, Davis BM, Mohs RC et al. (1984) Apomorphine and schizophrenia. Arch Gen Psychiatry 41: 520–524.
Mackay AVP (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137: 379–383.
Meltzer HY (1980) Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. Schizophr Bull 6: 456–475.
Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6: 329–338.
Olbrich R, Schanz H (1988) The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenia. Pharmacopsychiatry 21: 389–390.
Roth RH, Wolf ME, Deutch AY (1987) Neurochemistry of midbrain dopamine systems. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 81–94.
Seyfried CA, Greiner HE, Haase AF (1989) Biochemical and functional studies on EMD 49980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems. Eur J Pharmacol 160: 31–41.
Smith RC, Tamminga CA, Davis JA (1977) Effect of apomorphine on schizophrenic symptoms. J Neural Transm 40: 171–176.
Tamminga CA, Schaffer MH, Smith RC (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568.
Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660–669.
Weinberger DR, Bigelow LB, Kleinman JE, Klein ST, Rosenblatt JE, Wyatt RJ (1980) Cerebral venticular enlargement in chronic schizophrenia: an association with poor response to treatment. Arch Gen Psychiatry 37: 11–13.
Wiedemann K, Benkert O, Holsboer F (1990) B-HT 920 — a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23: 50–55.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wetzel, H., Hillert, A., Gründer, G. (1990). Behandlung der schizophrenen Negativsymptomatik mit Dopamin-Autorezeptor-Agonisten: Erste Erfahrungen mit Roxindol. In: Möller, HJ., Pelzer, E. (eds) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76263-5_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-76263-5_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-76264-2
Online ISBN: 978-3-642-76263-5
eBook Packages: Springer Book Archive